We sought to investigate the prognostic significance of prodromal angina (PA) in unselected patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) and its additive predictive value to the GRACE score.
Introduction
In patients with ST-segment elevation myocardial infarction (STEMI), primary percutaneous coronary intervention (PPCI) has emerged as the preferred reperfusion therapy to achieve early reperfusion, limit the infarct size, and ultimately reduce short and long-term fatality rates for MI. [1, 2] Despite obtaining a coronary flow restoration in most of the cases, mechanisms that determine the extent of myocardial damage are multifactorial and poorly understood. They mainly comprise the area at risk, the total ischemic time, reperfusion injury, microembolization, and microvascular obstruction. [3] It has been suggested that prodromal angina (PA) related to brief episode of myocardial ischemia before index MI (the so-called ischemic preconditioning) may contribute to limit the final infarct size. [4, 5] Two recent studies [6, 7] prospectively enrolling a small series of STEMI patients undergoing PPCI have shown that PA is independently associated with an increases myocardial savage and final infarct size as assessed with cardiac magnetic resonance. However, if these findings translate into an independent prognostic role of PA in the clinical setting of PPCI has not been established yet. Furthermore, whether the addition of PA to a current recommended GRACE risk score [8] improves the classification of risk has not been studied yet.
Therefore, the objectives of the present study were: to investigate the association between PA and 2-year cardiovascular mortality in an unselected cohort of STEMI patients undergoing PPCI and to evaluate its additive predictive value to the clinical risk model.
Material and methods
The present prospective cohort study (conceived in accordance with the principles of the most recent revision of the Declaration of Helsinki) was based on the database of one (S. OrsolaMalpighi Hospital) of the 2 centralized PPCI centers of the "Bologna STEMI hub and spoke network." [9, 10] This prospective database contains demographic information along with comprehensive clinical, electrocardiogram (ECG), procedural, and outcome data from STEMI patients treated with PPCI at the center's catheterization laboratory. The registry started in 2003 and was approved by the hospital's Ethics Committee. For the purpose of the present study, we include consecutive out-ofhospital STEMI patients treated with PPCI from January 1, 2003 to December 31, 2015. We excluded patients with missing data and those with coma at presentation owing to the difficulty of ascertaining the presence or not of PA.
STEMI was defined as significant ST-elevation (in 2 adjacent leads and 0.1 mV in leads I-III, aVF, aVL, V4-V6, and 0.2 mV in leads V1-V3) or in presence of STEMI-equivalent, namely newonset (or presumably new) left bundle branch block, posterior STEMI and ST-T de Winter complex. [11] Stenosis ≥50% in the lumen of left main artery or ≥70% in ≥1 of other major epicardial vessels or their main branches was considered significant. The culprit lesion was defined as the lesion with the highest degree of stenosis or in the presence of thrombolysis in myocardial infarction (TIMI) flow grade <3 or angiographic signs of endoluminal thrombi and/or plaque rupture. Coronary thrombus was defined as an intraluminal filling defect or an area of contrast staining within the coronary lesion. Plaque rupture was defined by the presence of a small crater or visible intimal flap. In case of TIMI flow <2, thrombotic coronary occlusion was defined on the basis of morphology and lack of collateral vessels. Percutaneous coronary intervention (PCI) was mainly performed within 12 hours of the self-reported onset of symptoms. Patients with symptom onset-to-STEMI diagnosis time interval between 12 and 24 hours were enrolled only in case of evident ongoing myocardial ischemia. Before PCI execution at the time of diagnosis, all patients received aspirin (250 mg i.v.) and heparin (5000 IU i.v). Vascular access, use of platelet glycoprotein IIb/IIIa agents, manual thrombectomy, and type of stent were at operator's discretion. After PCI, P2Y12 inhibitors were administered according to current guidelines.
Cardiac arrest was defined as cardiac arrest occurring before revascularization and requiring resuscitation procedures, (e.g., ventilation, chest compression, defibrillation).
PA was defined as ≥1 episodes of angina (Canadian cardiovascular Sociaty class ≥1) up to 3 months before the index episode, based on previous results. [7, 12] Study endpoint was cardiac mortality at 2-year follow-up. Cardiac death was defined as death from cardiac cause, sudden death, or any death without another known cause. In-hospital re-MI was defined as the recurrence of typical clinical symptoms and new ECG changes with an increase of MB Creatin-Kinase (MB-CK) above ≥ 50% of the previous levels. Out-of-hospital data concerning vital status of patients and cause of death were obtained by telephone interviews or independently from the Emilia-Romagna Regional Health Agency through the analysis of the Hospital Discharge Records and the Municipal Civil Registries, thus relying on treating physician's diagnosis.
Categorical data are expressed as proportions and continuous variables reported as mean (±SD) or medians medians (25 th -75 th percentiles). Patients were divided into 2 groups: those with no PA and patients with PA. For comparisons between groups, the x 2 test was used for categorical variables. Continuous variables were tested for normal distribution and tested using Student t or Mann-Whitney tests as appropriate.
The Kaplan-Meyer method was used to analyze the occurrence of events during follow-up. Study groups were compared by means of the log-rank Cox-Mantel test. Patients were censored at 2 years or at the time of the last contact. The relation to 2-year cardiac mortality of PA was investigated with the use of multivariable Cox regression model adjusted for variable selected at univariable analysis (P < .1). Thus, the following variables were entered in a multivariable backward selection: age, sex, smoking status, hypercholesterolemia, diabetes, hypertension, family history of coronary artery disease, previous MI, previous stroke, peripheral artery disease, systolic blood pressure and heart rate on admission, anterior MI, Killip class, cardiac arrest, creatinine levels on admission, left ventricle ejection fraction (LVEF), radial access, multivessel disease, GP IIb/IIIa inhibitors, pre and post TIMI flow grade, pain to balloon interval, and PA. Proportional hazard assumption was checked by Shoenfeld tests. Model discrimination was assessed using the Harrell C-index. [13] and confidence intervals were calculated using bootstraps estimation. Calibration was evaluated by the Groennesby and Borgan test approach for survival data, [14] with a x 2 ≥ 20 (P < .01) indicating poor calibration.
The additional contribution of PA to the GRACE risk score for prediction of study endpoint was evaluated in terms of classification accuracy measuring the continuous net reclassification improvement (NRI) as previously described. [15] Confident intervals were calculated using bootstraps estimation. A P value <.05 in the 2-tailed tests was considered significant. All analyses were performed with STATA 14.0 software (STATA Corporation, College Station, TX).
Results
During the study period, 3278 of hospital STEMI patients were treated with PPCI and enrolled in the prospective dataset of our Institution. For the purpose of the present study, 263 patients were excluded because of missing values and/or coma at admission (Fig. 1) . Thus, the final study cohort comprises 3015 of hospital STEMI patients undergoing primary angioplasty.
Baseline characteristics are listed in Table 1 . The mean age of the study population was 68 (± 14) years; 2178 patients (72%) were male. Among the study cohort, 685 (23%) had PA before the index MI. Patients with PA were generally younger than patients with no PA. They were more likely to be male and had a lower prevalence of hypertension, previous MI, and previous PCI. Patients with PA had a better clinical profile in terms of Killip class, LVEF, and pre-TIMI flow grade. They were more likely to receive radial access, drug-eluting stent (DES) implantation, and thrombus aspiration.
Overall, the rate of in-hospital mortality was 4.6% (Table 2 ). All deaths, but one (sepsis), were from cardiac origin. Patients with PA had a statistically significant lower rate of cardiac mortality than patients without PA (2.3% vs. 5.3%, respectively). There were no statistically significant differences in the rate of in hospital re-MI between the study groups ( Table 2) . Ghetti During a median follow-up of 2 years (only 34 [1.1%], patients had incomplete follow-up with a minimum value of 286 days), 395 patients died (13%). Of these, 278 patients (9.2%) suffered from cardiac mortality. The rates of both fatal and non-fatal re-MI were comparable ( Table 2) .
Kaplan-Meier estimates showed a survival rate of 95% and 87% for patients with PA and no PA, respectively (Fig. 2 , log rank test < 0.001).
After univariable and multivariable analysis, patients with PA had still a lower risk of 2 years cardiac mortality compared with patients without PA (adjusted hazard ratio [HR] = 0.50; 95% confidence interval [CI] 1.06-1.81, P = .001) ( Table 3) . The model showed good discrimination power (Harrell C = 0.876, 95% CI 0.858-0.897) and good calibration (Groennesby and Borgan x 2 = 8.065; P = .153). Evaluation of NRI showed that reclassification improved by 0.16% in case patients, whereas classification worsened in control patients by 1.08% leading to a NRI of À0.93% (95% CI: À0.98, À0.88). 
Discussion
The main findings of the present study enrolling 3015 unselected STEMI patients undergoing PPCI are as follows: patients with PA have a lower risk of 2-year cardiac mortality compared to those without; the incorporation of PA into the GRACE score does not improve classification of risk.
In acute MI with ST segment elevation the definite treatment is to rapidly restore coronary blood flow and myocardial perfusion with the objective of reducing infarct size and improve outcome. [1, 2] The size of the scar is directly associated with duration of myocardial ischemia. Previous studies have shown that PA leads to a more rapid reperfusion and smaller infarct size in patients with acute myocardial infarction treated with thrombolysis [16] with a mechanism not fully understood but likely involving ischemic preconditioning. [17, 18] In the setting of PPCI, 2 recent studies prospectively enrolling a small series of STEMI have shown that PA is independently associated with an increase myocardial savage and smaller final infarct size as assessed with cardiac magnetic resonance. [6, 7] However, if these findings translate into a favorable effect of PA on long-term prognosis has not been established, yet.
In the present study, enrolling a large cohort of STEMI patients undergoing PPCI, we show that those experiencing episode of angina up to 3 months before the index episode have a lower risk of cardiac mortality. Patients with PA have a better risk profile in terms of some characteristics such as diabetes and DES utilization and this could be partly account for its prognostic role. However, the strength of this finding relies on a comprehensive multivariable adjustment including also the LVEF, a main prognosticators of long-term prognosis after MI. [19] Of note, the rates of MI during follow-up between the study groups were comparable confirming that PA exercises its protective role reducing both the risk of life-threatening arrhythmias [20, 21] and the risk of heart failure [22] in keeping with the theory that ischemic preconditioning reduces the infarct size and favors the post-ischemic recovery of global ventricular function. [23] In particular, the risk of lifethreatening arrhythmias remains high in post-MI survivors with a mortality rate of 25% at 2 years. [24] Along with prompt revascularization, optimal medical therapy counteracting negative cardiac remodeling and implantable cardioverter defibrillator are mainstay therapies to prevent death in patients with post-MI LV dysfunction.
Findings of our study contrast with those of a previous study that did not show a prognostic relevance of PA on the clinical course of STEMI patients undergoing PPCI. [25] However, there are several differences between this study and ours that could explain the conflicting results.
First, we chose as primary endpoint the rate of long-term cardiac mortality, instead of in-hospital mortality, to better elucidate the cardiac consequences of PA in STEMI. Second, our sample size was 4-fold larger than the other one. Finally, patients of the present study were enrolled almost a decade later compared to those of the above mentioned study and had been treated in the context of current recommended strategies (clopidogrel and new P2Y12 inhibitors, DES, thrombus aspiration, radial access). Yet, to our knowledge, this is the first study that evaluates the additive contribution of PA to the GRACE score in a large unselected cohort of STEMI patients. We found that although PA independently stratifies risk of future cardiovascular death, there is no advantage in adding it to the GRACE score. On the contrary, we observed a slight worsening of risk classification.
The study is a prospective analysis of a single-center registry and it is not immune to sources of bias. Although we tried to control our results for known prognostic factors by means of multivariable analysis, the influence of other confounding factors cannot be ruled out. In particular, we did not collect information on the presence of collateral flow. However, it is known that in the context of acute coronary occlusion an efficient collateral flow is rarely observed. Besides, it has been recently shown that the presence of collateral flow has no protective role in terms of infarct size. [7] We did not collect information on LVEF during follow-up. This is a crucial aspect as it is known that after coronary revascularization a LV function recovery may occur, usually within 1 month [26] . Thus, it would have been desirable to test the association between PA and left ventricle function recovery in order to provide information on the mechanisms linking PA and better outcome. In conclusion, in patients with STEMI undergoing PPCI, the presence of PA is independently associated with a lower risk of 2-year cardiac mortality. However, the incorporation of this variable to the GRACE score slightly worsens the classification of risk. Accordingly, its utility in clinical practice appears unlikely.
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